Share ownership Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
52.52 ^USD	-2.43%		-1.96%	+78.09%

05/03	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
05/03	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE

Share class: Moderna, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	38,48,17,811	34,81,69,765 ( 90.48 %)	0	90.48 %

Major shareholders: Moderna, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.64 %	4,15,84,782	10.64 %	1 833 M $
Fidelity Management & Research Co. LLC 7.178 %	2,80,45,311	7.178 %	1 236 M $
BlackRock Advisors LLC 6.69 %	2,61,38,899	6.69 %	1 152 M $
Stéphane Bancel 5.621 %	2,19,63,357	5.621 %	968 M $
Baillie Gifford & Co. 5.267 %	2,05,80,514	5.267 %	907 M $
STATE STREET CORPORATION 4.188 %	1,63,65,478	4.188 %	721 M $
Capital Research & Management Co. (World Investors) 3.283 %	1,28,28,040	3.283 %	565 M $
Geode Capital Management LLC 2.36 %	92,19,644	2.36 %	406 M $
Eaton Vance Management 2.27 %	88,70,716	2.27 %	391 M $
Thélème Partners LLP 2.068 %	80,81,810	2.068 %	356 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Banco Santander Brasil SA (Private Banking) 0.000006 %	451	0.000006 %	995 $

Breakdown by shareholder type

Institutional	65.65%
Other	7.4%
Individuals	6.76%
State Street Corp.	4.19%
Merck & Co., Inc.	0.59%
Schweizerische Nationalbank	0.18%
Governments	0.12%
Manulife Financial Corp.	0.11%
SEI Investments Co.	0.04%
Banco Bilbao Vizcaya Argentaria SA	0.02%
The Bank of Nova Scotia	0.02%
Sumitomo Mitsui Trust Group, Inc.	0.01%
Fifth Third Bancorp	0.01%
Meitav Investment House Ltd.	0.01%
Unknown	14.89%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	61.21%
United Kingdom	11.76%
Individuals	6.76%
Switzerland	1.39%
Norway	0.71%
Ireland	0.66%
Canada	0.59%
Australia	0.48%
France	0.44%
Singapore	0.19%
Luxembourg	0.18%
Japan	0.15%
Hong Kong	0.14%
Spain	0.12%
Germany	0.09%
British Virgin Islands	0.08%
China	0.04%
Sweden	0.03%
Czech Republic	0.03%
Israel	0.02%
Italy	0.02%
Netherlands	0.01%
Denmark	0.01%

Based on 1000 largest holdings

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company